Fatigue can also have multiple causes in people taking GLP-1 medications, including reduced caloric intake, which makes attribution complex
Despite increased GLP-1 levels and incretin receptor expression on beta cells, the lower glucose levels achieved with metformin treatment were not associated with increased insulin levels [10]
and retatrutide (Lilly), a novel triple agonist of GIP, GLP-1 and glucagon receptors, have considerable potential because they are potent at inducing weight loss
Glutathione for Skin: Uses, Side Effects and More Which Serum Is Best for Glowing Skin
The reasons are both scientific and practical: Scientific rationale: Combination administration confounds mechanistic analysis you can't attribute observed effects to a specific compound Receptor saturation means diminishing returns from redundant agonism Novel adverse event profiles from untested combinations introduce uncontrolled variables Practical considerations: Retatrutide already encompasses semaglutide's entire receptor profile plus two additional pathways Research compound costs double with no established mechanistic justification No published protocol exists for combined dosing, titration, or timing For researchers deciding between these compounds individually, our retatrutide vs semaglutide comparison covers the trade-offs in depth